表紙
市場調査レポート

肺疾患ドラッグデリバリー技術

Pulmonary Drug Delivery Technologies

発行 Global Industry Analysts, Inc. 商品コード 121099
出版日 ページ情報 英文 599 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
肺疾患ドラッグデリバリー技術 Pulmonary Drug Delivery Technologies
出版日: 2010年04月01日 ページ情報: 英文 599 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、世界の肺疾患ドラッグデリバリー技術市場について分析し、肺疾患の概要と治療法、肺へのドラッグデリバリーの概要とともに、市場に参入する企業のプロファイルと各国市場別の動向などをまとめ、概略以下の構成でお届けします。

第1章 イントロダクション、調査方法、製品定義

第2章 エグゼクティブサマリー

  • 業界概要
    • ドラッグデリバリー技術:概要
    • 肺疾患ドラッグデリバリー
    • 動向と課題
  • 製品概要
    • 肺疾患ドラッグデリバリーシステムの定義
    • 肺疾患ドラッグデリバリーシステムのメリット
    • 肺疾患ドラッグデリバリー装置
      • 主な特徴
      • 吸入器
      • ネブライザー
      • 吸入装置の臨床的効果に影響を及ぼす要因
  • 肺疾患の症状と治療概要
    • 呼吸器系
    • 肺疾患ドラッグデリバリー:概要
    • 喘息および慢性閉塞性肺疾患
    • 肺を通じたドラッグデリバリー法
    • 肺投薬アプローチ
  • 製品革新/導入
  • 近年の業界動向
  • 主要参入企業
    • 3M Drug Delivery Systems Division
    • Akela Pharma Inc
    • Alkermes, Inc.
    • Aradigm Corporation
    • AstraZeneca Plc
    • Baxter International Inc.
    • Chiesi Farmaceutici SpA
    • Consort Medical Plc
    • Dey Pharma L.P.
    • GlaxoSmithKline Plc
    • Graceway Pharmaceuticals, LLC
    • NovartiS AG
    • Oriel Therapeutics, Inc.
    • Sepracor, Inc.
    • SkyePharma Plc
    • Valois S.A.S.
    • Vectura Group Plc
  • 世界市場見通し

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • スペイン
    • ロシア
    • その他
  • アジア太平洋諸国
  • ラテンアメリカ
  • その他の諸国

第3章 競合環境

  • 企業プロファイル
    • 米国
    • カナダ
    • 日本
    • 欧州
    • 中東
目次
Product Code: MCP-1244

This report analyzes the worldwide markets for Pulmonary Drug Delivery Technologies in US$ Million by the following Product Segments: Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), and Others. The report provides separate comprehensive analytics for US, Canada, Japan, Europe, Asia Pacific, Latin America, and Rest of the World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 61 companies including many key and niche players such as 3M Drug Delivery Systems Division, Akela Pharma Inc., Alkermes, Inc., Aradigm Corporation, AstraZeneca Plc, Baxter International Inc., Chiesi Farmaceutici SpA, Consort Medical Plc, Dey Pharma L.P., GlaxoSmithKline Plc, Graceway Pharmaceuticals, LLC, NovartiS AG, Oriel Therapeutics, Inc., Sepracor, Inc., SkyePharma Plc, Valois S.A.S, and Vectura Group Plc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
  • Metered Dose Inhalers (MDIs)
  • Dry Powder Inhalers (DPIs)
  • Others
  • Nebulizers

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Drug Delivery Technologies: A Primer
  • Table 1: Worldwide Drug Delivery Market (2007): Percentage Share Breakdown of Revenue by Technology Segment (includes corresponding Graph/Chart)
  • Drug Delivery Technologies Turns Critically Important to Pharma Majors
  • The Need for Novel Drug Delivery Technologies From A Financial Standpoint
  • Pulmonary Drug Delivery: A Preferred, Non-Invasive Drug Administration Route
  • Market Fundamentals: A Current Review
  • Respiratory Disorders: A Large & Mature Therapeutic Category
  • Widely Prescribed Inhalation Drugs for Asthma & COPD
  • Inhaler Devices: An Integral Part of Pulmonary Drug Delivery
  • Pulmonary Delivery of Systemic Drugs: A Future Growth Area
  • Delivering Macromolecules Through the Lungs: A Current Focus Area
  • Innovations in Inhalation Aerosols
  • Current Drugs in Pipeline: A Review
  • Inhaled Drugs in Pipeline as of the Year 2008 & 2009
  • Noteworthy Trends & Issues
  • Nanotechnology Makes its Presence Felt in Inhaled Drugs
  • Innovation in Inhaler Devices: A Key Differentiating Factor
  • Innovation is the Name of the Game in the Nebulizer Segment
  • Nebulizers for Pediatric Care: Need of the Hour
  • CFC Propellants Give Way to HFA
  • Chinks in MDI' s Armor Work in Favor of DPI Market
  • Potential Challenges for DPI Market
  • Combination Therapy: An Effective Strategy in Optimum Disease Management

2. PRODUCT OVERVIEW

  • Definition of Pulmonary Drug Delivery System
  • Benefits of Pulmonary Drug Delivery Systems
  • Therapeutic Benefits
  • Titration by Therapy
  • Titration by Patient
  • Dose Reproducibility
  • High Bioavailability
  • Other Key Advantages
  • Pulmonary Drug Delivery Devices
  • An Overview of Key Features of Popular Inhalation Devices
  • Inhalers
  • Metered Dose Inhalers (MDIs)
  • Working Principle of an MDI
  • CFC-Propellant based MDIs
  • Ban on CFCs
  • Use of Spacers in MDIs
  • Benefits of Spacers
  • Pros & Cons
  • Advantages
  • Unique Benefits of pMDIs
  • Limitations
  • Issues
  • MDIs & Future
  • Dry Powder Inhalers (DPIs)
  • Inspiratory Flow Rate in DPIs
  • Working Principle of DPIs
  • Deaggregation in Dry Powder Inhalers (DPIs)
  • Types of DPIs
  • Passive DPI
  • Active DPI
  • Single-dose DPIs
  • Multi-dose DPIs
  • Other Types
  • Benefits of DPIs
  • Limitations
  • Issues
  • In a nutshell
  • Comparison with MDIs
  • Nebulizers
  • Working Principle of a Nebulizer
  • Use of UDMs in Nebulizers
  • Types of Nebulizers
  • Ultrasonic Nebulizers
  • Gray Areas
  • Benefits
  • Limitations
  • Pneumatic Nebulizers
  • Breath-Actuated Nebulizers
  • Continuous Nebulization
  • Active Venturi Nebulizers
  • New Designs for Improved Nebulizer Performance
  • Limitations of Nebulizers
  • Factors Influencing Clinical Effectiveness of Inhalation Device
  • Device Factors
  • Patient Factors
  • Drug Factors

3. AN OVERVIEW OF PULMONARY CONDITIONS

AND THERAPIES
  • The Respiratory System
  • Pulmonary Drug Delivery - An Overview
  • Asthma and COPD - Major Respiratory Disease Conditions
  • Asthma: Primary Respiratory Syndrome
  • Trigger Factors
  • Magnitude of Disease
  • Chronic Obstructive Pulmonary Disease
  • Magnitude of Disease
  • Treatment of Asthma and COPD
  • Methods of Drug Delivery through Pulmonary Route
  • Aerosols Systems
  • Intratracheal Inhalation
  • Insufflation
  • Pulmonary Delivery Approaches
  • Controlled Release
  • Drug Medications for Treating Asthma and COPD
  • Bronchodilators (Acute Reliever Drugs)
  • Categories of Bronchodilators
  • Short acting beta-agonists
  • Long acting beta-agonists
  • Anti-cholinergics
  • Methylxanthines
  • Combination Bronchodilators
  • Available Inhaled Locally Acting Drugs
  • Anti-Inflammatory Medication (Controllers or Preventers)
  • Corticosteroids
  • Inhaled Corticosteroids in Asthma
  • Inhaled Corticosteroids in COPD
  • Anti-Leukotrienes
  • Innovative Therapeutic Approaches
  • Combination Therapeutics

4. PRODUCT INNOVATIONS/INTRODUCTIONS

  • Pearl Therapeutics Announces Phase II Trials of Glycopyrrolate Inhalation Aerosol in COPD
  • PARI Receives Patent for Vortex Holding Chamber
  • Schering-Plough Obtains Approval for Asmanex in Japan
  • SkyePharma Inc Receives FDA Communication on Flutiform
  • Almirall Announces Positive Results of Phase III Eklira
  • MicroDose Therapeutx Initiates Phase 1 Study with Inhaled Atropine
  • PARI Pharma Announces Successful Phase Ib Results for Inhaled L-CsA
  • PARI Respiratory Launches PEP S
  • 3M Drug Delivery Systems Rolls Out 3M Conix DPI, 3M Taper DPI
  • Akela Pharma Achieves Third Milestone in Fentanyl TAIFUN(r) Phase III Study
  • Vectura Group Announces Phase III Trials for NVA237, QVA149
  • Novartis Gets EU Approval for Onbrez(r) Breezhaler(r)
  • Novartis Gets Complete Response Letter for QAB149, from US FDA
  • Novartis Obtains EU Approval for Xolair(r) for Treating Severe Asthma in Children Under 11 Years
  • AstraZeneca Gets FDA Complete Response Letter for Symbicort in Paediatric Patients
  • AstraZeneca Gets FDA Approval for Symbicort in COPD
  • 3M Drug Delivery Systems Unveils 3M Face Seal Valve, 3M Plasma Coating Technology
  • Nanotechnology Victoria, Monash University Develops SAW Generated Mechanism
  • RTS Life Science Rolls Out Automated Inhaler Testing Solution
  • Eli Lilly &Co and Alkermes Abandon Inhaled Insulin Development Deal
  • Novo-Nordisk Drops Development Plan of Inhaled Insulin
  • Concomitant Use of Tiotropium, Nebulized Formoterol Fumarate to Relieve COPD Symptoms
  • Advair Gets FDA Nod for Advair 250/50

5. RECENT INDUSTRY ACTIVITY

  • Dainippon Sumitomo Concludes Acquisition of Sepracor
  • MicroDose Therapeutx Acquires ViroPharma Investigational Compounds
  • Sepracor Grants Non-Exclusive License for XOPENEX(r) to Teva and Barr
  • Skyepharma, Novartis Terminate Formoterol Certihaler Deal
  • Tidal Air to Sell Matrix Aerosol Delivery System
  • Battelle Memorial Institute Purchases Assets of Ventaira Pharmaceuticals Inc
  • Aptar Pharma to Roll Out Pulmonary & Nasal Devices In India
  • 3M Drug Delivery Systems Unveils New Singaporean Facility
  • Forest Laboratories, Almirall, Extend Collaboration for LAS100977
  • MicroDose Therapeutx, Merck Expand Collaboration Deal
  • AstraZeneca Sells API Facility to Minakem
  • ALR Technologies, Pari Enter Into Agreement
  • Akela Adds Amendment Into Fentanyl TAIFUN(r) License Deal with Teikoku Seiyaku
  • Novartis, Schering-Plough Revise Collaboration Terms
  • Astellas, AstraZeneca Ink Co-Promotion Agreement for Symbicort Turbuhaler
  • Iroko Cardio Inks Distribution Agreement with Chiesi Farmaceutici
  • Novartis Completes Acquisition of Nektar' s Pulmonary Business
  • 3M, Cambridge Consultants Forge Licensing Deal for DPI Technology
  • Savara Relocates Headquarters to Texas
  • GSK to Take Over Genelabs Technologies Inc
  • Novo Nordisk Hand Over Inhaled Insulin Patents to Aradigm
  • Sepracor Enters Into Agreement with Arrow International
  • Royal Philips Electronics Acquires Medel, Melhk
  • Aerogen Concludes Management Buyout from Nektar
  • Valois Pharma Bags Multi Million Contract

6. FOCUS ON SELECT PLAYERS

  • 3M Drug Delivery Systems Division (USA)
  • Akela Pharma Inc (Canada)
  • Alkermes, Inc. (USA)
  • Aradigm Corporation (USA)
  • AstraZeneca Plc (UK)
  • Baxter International Inc. (USA)
  • Chiesi Farmaceutici SpA (Italy)
  • Consort Medical Plc (UK)
  • Dey Pharma L.P. (USA)
  • GlaxoSmithKline Plc (UK)
  • Graceway Pharmaceuticals, LLC (USA)
  • NovartiS AG (Switzerland)
  • Oriel Therapeutics, Inc. (USA)
  • Sepracor, Inc. (USA)
  • SkyePharma Plc (UK)
  • Valois S.A.S. (France)
  • Vectura Group Plc (UK)

7. GLOBAL MARKET PERSPECTIVE

  • Table 2: World Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
  • Table 3: World Historic Review for Pulmonary Drug Delivery Technologies by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
  • Table 4: World 13-Year Perspective for Pulmonary Drug Delivery Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets for Years 2003, 2009, and 2015 (includes corresponding Graph/Chart)
  • By Product Segments
  • Table 5: World Recent Past, Current and Future Analysis for Metered Dosage Inhalers (MDIs) by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
  • Table 6: World Historic Review for Metered Dosage Inhalers (MDIs) by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
  • Table 7: World 13-Year Perspective for Metered Dosage Inhalers (MDIs) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets for Years 2003, 2009, and 2015 (includes corresponding Graph/Chart)
  • Table 8: World Recent Past, Current and Future Analysis for Dry Powder Inhalers (DPIs) by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015(includes corresponding Graph/Chart)
  • Table 9: World Historic Review for Dry Powder Inhalers (DPIs) by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
  • Table 10: World 13-Year Perspective for Dry Powder Inhalers (DPIs) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets for Years 2003, 2009, and 2015 (includes corresponding Graph/Chart)
  • Table 11: World Recent Past, Current and Future Analysis for Other Pulmonary Drug Delivery Technologies by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
  • Table 12: World Historic Review for Other Pulmonary Drug Delivery Technologies by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
  • Table 13: World 13-Year Perspective for Other Pulmonary Drug Delivery Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets for Years 2003, 2009, and 2015 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Outlook
    • Current Market Scenario
    • Major Growth Areas/Indicators
    • Respiratory Diseases
    • Cancer
    • Cystic Fibrosis
    • HFA Albuterol Eats into CFC Inhalers Market
    • Table 14: US Albuterol Inhalers Market in Aerosol Beta Agonists Category (2006 & 2007): Percentage Share Breakdown of Revenue by Product Type (includes corresponding Graph/Chart)
    • New & Popular DPIs in the US
    • Nebulizers: Displaying Promising Growth
    • Table 15: US Nebulizers Market (2008): Percentage Share Breakdown of Revenues by Segment (includes corresponding Graph/Chart)
    • Role of FDA
    • Key Market Share Findings
    • Table 16: US Bronchodilators Market (2006): Percentage Share Breakdown of Revenues by Key Players (includes corresponding Graph/Chart)
    • Table 17: US Anti-Inflammatory Market (2006): Percentage Share Breakdown of Revenues by Key Players (includes corresponding Graph/Chart)
    • Table 18: US Bronchodilators Market (2009): Percentage Share Breakdown of Revenues by Segment (includes corresponding Graph/Chart)
    • Table 19: US Anti-Inflammatory Market (2006): Percentage Share Breakdown of Revenues by Segment (includes corresponding Graph/Chart)
    • Product Launches/Developments
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 20: US Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
    • Table 21: US Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
    • Table 22: US 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Outlook
    • Product Launch
    • Strategic Corporate Developments
    • Akela Pharma Inc - A Key Canadian Player
  • B. Market Analytics
    • Table 23: Canadian Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
    • Table 24: Canadian Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
    • Table 25: Canadian 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Outlook
    • Product Launch
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 26: Japanese Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
    • Table 27: Japanese Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
    • Table 28: Japanese 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Outlook
    • Growth Drivers
    • Table 29: European Drug Delivery Market: Number of Deals Between Pharmaceutical/ Biotechnology Companies and Drug Delivery Companies for 2004 & 2007
    • Focus of R&D Shifts to Diabetes Treatment
    • Table 30: Research Activity Distribution in the European Pulmonary Drug Delivery Market (2007): Percentage Share Breakdown of Activity by Therapeutic Area (includes corresponding Graph/Chart)
    • European Pulmonary Drug Delivery Market: Drugs In Clinical Pipeline As of 2007
    • DPIs in Europe
    • Product Launches/Developments
    • Strategic Corporate Developments
    • Novartis Ag (Switzerland) - A Key European Player
  • B. Market Analytics
    • Table 31: European Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
    • Table 32: European Historic Review for Pulmonary Drug Delivery Technologies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
    • Table 33: European 13-Year Perspective for Pulmonary Drug Delivery Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2003, 2009 and 2015 (includes corresponding Graph/Chart)
    • Table 34: European Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
    • Table 35: European Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
    • Table 36: European 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Outlook
    • Strategic Corporate Development
    • Valois S.A.S. - A Key Player
  • B. Market Analytics
    • Table 37: French Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
    • Table 38: French Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
    • Table 39: French 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

4b. GERMANY

  • Market Analysis
  • Table 40: German Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
  • Table 41: German Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
  • Table 42: German 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

4c. ITALY

  • A. Market Analysis
    • Outlook
    • Chiesi Farmaceutici SpA - A Key Player
  • B. Market Analytics
    • Table 43: Italian Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
    • Table 44: Italian Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
    • Table 45: Italian 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Outlook
    • Market Overview
    • Areas of Growth
    • Progress in Drug Delivery
    • Product Launches/Developments
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 46: UK Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
    • Table 47: UK Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
    • Table 48: UK 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
  • Table 49: Spanish Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
  • Table 50: Spanish Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
  • Table 51: Spanish 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

4f. RUSSIA

  • Market Analysis
  • Table 52: Russian Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
  • Table 53: Russian Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
  • Table 54: Russian 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • Market Analysis
  • Table 55: Rest of Europe Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
  • Table 56: Rest of Europe Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
  • Table 57: Rest of Europe 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Outlook
    • Regional Snapshot
    • India
    • Nebulizers Market in India: A Quick Primer
    • Dry Powder Inhalers for Children
    • Product Launch
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 58: Asia-Pacific Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
    • Table 59: Asia-Pacific Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
    • Table 60: Asia-Pacific 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • Market Analysis
  • Table 61: Latin American Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
  • Table 62: Latin American Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
  • Table 63: Latin American 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • Market Analysis
  • Table 64: Rest of World Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
  • Table 65: Rest of World Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
  • Table 66: Rest of World 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top